Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbCellera Biologics has the GF Score of 60, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes AbCellera Biologics
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
AbCellera Biologics GF Score Related Terms
HAM:8QQ vs AGIO, KOD, IMNM: GF Score Comparison
For the Biotechnology subindustry, AbCellera Biologics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's GF Score distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's GF Score falls into.
AbCellera Biologics (HAM:8QQ) has a GF Score of 60 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on AbCellera Biologics and its competitors. This is 62% above median its historical median of 37.00. Over the past decade, AbCellera Biologics' GF Score has ranged from 16.00 to 76.00.
Is AbCellera Biologics' GF Score too high?
AbCellera Biologics' current GF Score of 60 is 62% above median its 10-year median of 37.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 76.00. Overall, AbCellera Biologics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' GF Score compare to AGIO and KOD?
AbCellera Biologics' GF Score of 60 can be compared against companies in the Biotechnology industry. Historically, AbCellera Biologics' own GF Score has ranged from 16.00 to 76.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current GF Score is 60, which is 62% above median its own 10-year median of 37.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (HAM:8QQ) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.84, compared to a current price of €5.90 — trading 21.9% above its estimated fair value. The current GF Score is 60, which is 62% above median its 10-year median of 37.00. AbCellera Biologics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For AbCellera Biologics (HAM:8QQ), the current GF Score is 60 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (HAM:8QQ) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of €5.90 is trading 21.9% above its estimated GF Value™ of €4.84.
GuruFocus considers AbCellera Biologics to be Modestly Overvalued.
Key valuation signals for HAM:8QQ:
GF Score: 60 (62% above median its 10-year median of 37.00)
GF Value™: €4.84 vs. price of €5.90 (21.9% above fair value)
No single metric tells the full story. See the HAM:8QQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
60GF Score
Get the complete analysis for HAM:8QQ
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:8QQ has been successfully added to your 
